Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
Launched by UNIVERSITY OF AARHUS · May 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the long-term effects of post-surgical hypoparathyroidism, a condition that affects hormone levels and can impact bone, kidney, and heart health. Researchers want to find out if patients with this condition have problems like stiff arteries, more heart plaque, or increased risk of bone fractures compared to healthy individuals of the same age and gender. To gather this information, participants will undergo several tests including CT scans, bone density scans, and blood tests, along with completing questionnaires and providing a urine sample.
You might be eligible to participate if you are at least 18 years old, have been diagnosed with chronic post-surgical hypoparathyroidism for over five years (or at least one year if needed), and are currently taking a specific dose of vitamin D. Healthy individuals without a history of neck surgery or parathyroid disease can also be part of the study as control participants. It's important to note that certain health conditions, such as serious kidney issues or recent cancer treatment, would exclude you from participating. If you join, you'll contribute to important research that could help improve understanding and treatment of this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients only:
- • Chronic post surgical hypoparathyroidism diagnosed \> 5 years ago. (In case recruitment is too challenging, we will accept duration of disease of minimum one year. Including patients with longest duration of disease first.)
- • Require treatment with active vitamin D ≥ 1 µg/day
- Controls only:
- • No history of neck surgery
- • No history of parathyroid disease
- All participants:
- • Age ≥ 18 years
- • 25(OH)D vitamin ≥ 50 nmol/L
- • Serum magnesium ≥ 0,50 mmol/L
- • Able to read and understand Danish
- • Willing and able to sign the informed consent form
- Exclusion Criteria:
- • Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m3
- • Active cancer or former (except thyroid and basal cell skin) cancer treatment \< 5 year ago
- • Pregnancy, or breastfeeding \< 1 year ago
- • Untreated thyroid or liver diseases during the last year
- • Treatment with lithium within the last 4 weeks
- • Known allergy or sensitivity to iodine
- • Any reason that in the opinion of the investigator, that would prevent the patient from completing the study.
About University Of Aarhus
The University of Aarhus, a prestigious research institution located in Denmark, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment that encourages cutting-edge research and the development of novel therapeutic interventions. Committed to ethical standards and patient safety, the University of Aarhus aims to contribute to the global body of medical knowledge while enhancing healthcare outcomes through rigorous scientific inquiry and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aarhus N, , Denmark
Patients applied
Trial Officials
Lars Rejnmark
Principal Investigator
Aarhus University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported